On the other hand, the benefits of FGF21 therapeutics include improvement of the atherogenic lipid profile, hepatic fat fraction, and markers of liver damage and fibrosis, making these compounds promising for treatment strategies in NAFLD and NASH patients. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.